Topic Spotlight

Multiple Sclerosis

PCORI Answers Critical Questions

Evidence gaps can make it difficult to know which multiple sclerosis treatment will work best given a patient’s needs. PCORI funds studies that seek to help patients, clinicians and others answer various questions they might have about treatment options, such as:

Patient: I’m over 55 and my MS has been stable for years. Should I stay on my disease-modifying drug or consider a different treatment?

Clinician: In my rural community, would telerehabilitation be as effective as in-clinic rehabilitation? Would it provide a good option for patients without easy access to MS specialty centers?

Patient: Which of the available medications work best to treat my fatigue?

Multiple Sclerosis Study Spotlights

Drugs for Relapsing-Remitting MS

This study compares how well two disease-modifying medicines, fingolimod and dimethyl fumarate, prevent relapses in patients with the relapsing-remitting form of MS.

People Involved in MS Research

Hear about several comparative clinical effectiveness research studies that aim to help patients and those who care for them make better-informed decisions about their options for treating MS.

Clinic versus Home-Based MS Therapy

Clinics that provide exercise, yoga, and other nondrug therapies are scarce in rural and low-income areas. This study compares the benefits of an exercise program when patients receive it in a clinic versus at home via internet or telephone.

Multiple Sclerosis Portfolio Snapshots

Multiple Sclerosis portfolio - most studied populations of interest
Older adults 3
Racial/ethnic minorities 1
Urban 2
Low socioeconomic status 1
Individuals with disabilities 4
Women 3
As of September 2017
57% of PCORI's 12 funded studies related to multiple sclerosis focus on comparative effectiveness of drug therapies. As of September 2017